Last reviewed · How we verify
Aspirin and clopidogrel/Ticagrelor
This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways.
This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-myocardial infarction, Stroke prevention.
At a glance
| Generic name | Aspirin and clopidogrel/Ticagrelor |
|---|---|
| Sponsor | Beijing Neurosurgical Institute |
| Drug class | Dual antiplatelet agent |
| Target | COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel and ticagrelor are P2Y12 receptor antagonists that block adenosine diphosphate (ADP)-mediated platelet aggregation. Together, this dual antiplatelet therapy provides synergistic inhibition of platelet function to prevent thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention of cardiovascular events post-myocardial infarction
- Stroke prevention
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Headache
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: